Artgen Biotech Company (ex. Human Stem Cell Institute, MOEX: ABIO) will take part in the 2023 OpenBio Forum.
OpenBio is a major interregional event in the field of biotechnology and biopharmaceuticals which will be held in the Koltsovo Science Town, Novosibirsk region, for the 10th time this year. At the event, development of the bio industry, business, advanced scientific achievements, and global trends are discussed.
Sergey Masyuk, Artgen Biotech’s CEO, will speak at the “Investment: New Times” round table and describe how Artgen Biotech’s internal ecosystem helps the group’s companies achieve IPO readiness.
Artgen Biotech is a biotechnology company whose goal is to create, develop, and implement in medical practice innovative drugs, devices or treatment, diagnostics, and prevention methods that provide new means to combat socially significant and orphan diseases that are more effective than the existing ones. The company was founded in 2003. Since 2009, it has been an issuer at the Moscow Exchange Innovation and Investment Market.
The Artgen Biotech group includes companies at different development stages, from seed to early growth and maturity. Artgen is a strategic investor in industries that improve the efficiency and quality of medical care.
Artgen Biotech is developing an internal ecosystem to accelerate the group’s biotech companies and commercialize their developments. The ecosystem translates the unique expertise in science, regulation, research, medicine, production, patents, marketing, investment to companies.
On April 25, 2023, during its IPO on the Moscow Exchange, an Artgen Biotech company, Genetico (Genetics and Reproductive Medicine Center, MOEX: GECO), placed 10 million shares and raised RUB 178.8 million. The order book was oversubscribed by 2.5 times.
In July 2023, a vaccine developer company of the Artgen Biotech group, RBT (BioTechnology Developments), held a pre-IPO on the Rounds investment platform and raised RUB 155 million. Thanks to Artgen Biotech’s ecosystem and support from Skolkovo investors, the offering was successful, at the top of the price range, with oversubscription. The book of orders from investors wishing to take part in the company’s first investment round reached more than RUB 251 million.
In 2019, during its IPO on the Moscow Exchange, an Artgen Biotech company, Gemabank (International Medical Center for Biomaterials, MOEX: GEMA), raised over RUB 150 million. Orders for the entire offering were collected within the first hour. Instead of the stated 5 days, the offering took 24 hours.